Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors
Titel:
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors
Auteur:
Hu-Lieskovan, S. Patnaik, A. Eisenberg, P. Sachdev, J. Weise, A. Kaufman, D.R. Aromin, I. West, B.L. Tong, S. Ribas, A.